High-rolling investors have positioned themselves bullish on Madrigal Pharmaceuticals MDGL, and it's important for retail traders to take note. \This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in MDGL often signals that someone has privileged information.
Today, Benzinga's options scanner spotted 9 options trades for Madrigal Pharmaceuticals. This is not a typical pattern.
The sentiment among these major traders is split, with 44% bullish and 44% bearish. Among all the options we identified, there was one put, amounting to $50,600, and 8 calls, totaling $2,289,644.
What's The Price Target?
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $200.0 to $380.0 for Madrigal Pharmaceuticals over the last 3 months.
Volume & Open Interest Trends
In today's trading context, the average open interest for options of Madrigal Pharmaceuticals stands at 337.17, with a total volume reaching 507.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Madrigal Pharmaceuticals, situated within the strike price corridor from $200.0 to $380.0, throughout the last 30 days.
Madrigal Pharmaceuticals Call and Put Volume: 30-Day Overview
Biggest Options Spotted:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MDGL | CALL | TRADE | BEARISH | 07/18/25 | $66.0 | $65.0 | $65.0 | $320.00 | $1.3M | 1.5K | 300 |
| MDGL | CALL | TRADE | BEARISH | 07/18/25 | $73.8 | $72.8 | $72.8 | $320.00 | $728.0K | 1.5K | 100 |
| MDGL | CALL | TRADE | BEARISH | 01/16/26 | $182.0 | $175.0 | $175.0 | $200.00 | $70.0K | 1 | 4 |
| MDGL | CALL | SWEEP | BULLISH | 12/19/25 | $69.9 | $68.4 | $68.4 | $380.00 | $68.4K | 4 | 0 |
| MDGL | PUT | TRADE | BEARISH | 04/17/25 | $25.0 | $19.5 | $23.0 | $340.00 | $50.6K | 31 | 22 |
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and non-alcoholic steatohepatitis (NASH). The product portfolio of the company includes MGL-3196, an orally administered, small-molecule liver-directed B-selective THR agonist, which is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. Also, MGL-3196 reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action.
After a thorough review of the options trading surrounding Madrigal Pharmaceuticals, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
Present Market Standing of Madrigal Pharmaceuticals
- With a volume of 357,841, the price of MDGL is down -4.98% at $338.15.
- RSI indicators hint that the underlying stock may be approaching overbought.
- Next earnings are expected to be released in 68 days.
Expert Opinions on Madrigal Pharmaceuticals
2 market experts have recently issued ratings for this stock, with a consensus target price of $437.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. Click here for access. * Consistent in their evaluation, an analyst from Citigroup keeps a Buy rating on Madrigal Pharmaceuticals with a target price of $469. * An analyst from HC Wainwright & Co. persists with their Buy rating on Madrigal Pharmaceuticals, maintaining a target price of $405.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Madrigal Pharmaceuticals, Benzinga Pro gives you real-time options trades alerts.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
